Year |
Citation |
Score |
2020 |
Rolfe A, Yao S, Nguyen TV, Omoto K, Colombo F, Virrankoski M, Vaillancourt FH, Yu L, Cook A, Reynolds D, Ioannidis S, Zhu P, Larsen NA, Bolduc DM. Discovery of 2,6-Dimethylpiperazines as Allosteric Inhibitors of CPS1. Acs Medicinal Chemistry Letters. 11: 1305-1309. PMID 32551016 DOI: 10.1021/Acsmedchemlett.0C00145 |
0.361 |
|
2020 |
Yao S, Nguyen TV, Rolfe A, Agrawal AA, Ke J, Peng S, Colombo F, Yu S, Bouchard P, Wu J, Huang KC, Bao X, Omoto K, Selvaraj A, Yu L, ... ... Larsen NA, et al. Small Molecule Inhibition of CPS1 Activity through an Allosteric Pocket. Cell Chemical Biology. PMID 32017919 DOI: 10.1016/J.Chembiol.2020.01.009 |
0.339 |
|
2018 |
Puyang X, Furman C, Zheng GZ, Wu ZJ, Banka D, Aithal B K, Agoulnik S, Bolduc DM, Buonamici S, Caleb B, Das S, Eckley S, Fekkes P, Hao MH, Hart A, ... ... Larsen N, et al. Discovery of Selective Estrogen Receptor Covalent Antagonists (SERCAs) for the treatment of ERa(WT) and ERa(MUT) breast cancer. Cancer Discovery. PMID 29991605 DOI: 10.1158/2159-8290.Cd-17-1229 |
0.315 |
|
2018 |
Cretu C, Agrawal AA, Cook A, Will CL, Fekkes P, Smith PG, Lührmann R, Larsen N, Buonamici S, Pena V. Structural Basis of Splicing Modulation by Antitumor Macrolide Compounds. Molecular Cell. PMID 29656923 DOI: 10.1016/J.Molcel.2018.03.011 |
0.383 |
|
2018 |
Gingipalli L, Block MH, Bao L, Cooke E, Dakin LA, Denz CR, Ferguson AD, Johannes JW, Larsen NA, Lyne PD, Pontz TW, Wang T, Wu X, Wu A, Zhang HJ, et al. Discovery of 2,6-disubstituted pyrazine derivatives as inhibitors of CK2 and PIM kinases. Bioorganic & Medicinal Chemistry Letters. PMID 29559278 DOI: 10.1016/J.Bmcl.2018.03.018 |
0.319 |
|
2018 |
Finci LI, Zhang X, Huang X, Zhou Q, Tsai J, Teng T, Agrawal A, Chan B, Irwin S, Karr C, Cook A, Zhu P, Reynolds D, Smith PG, Fekkes P, ... ... Larsen NA, et al. The cryo-EM structure of the SF3b spliceosome complex bound to a splicing modulator reveals a pre-mRNA substrate competitive mechanism of action. Genes & Development. 32: 309-320. PMID 29491137 DOI: 10.1101/Gad.311043.117 |
0.374 |
|
2018 |
Korpal M, Puyang X, Furman C, Zheng G, Banka D, Wu J, Zhang Z, Thomas M, Mackenzie C, Yao H, Rimkunas V, Kumar P, Caleb B, Karr C, Subramanian V, ... ... Larsen N, et al. Abstract P1-10-08: Development of a first-in-class oral selective ERα covalent antagonist (SERCA) for the treatment of ERαWT and ERαMUT breast cancer Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-P1-10-08 |
0.312 |
|
2017 |
Teng T, Tsai JH, Puyang X, Seiler M, Peng S, Prajapati S, Aird D, Buonamici S, Caleb B, Chan B, Corson L, Feala J, Fekkes P, Gerard B, Karr C, ... ... Larsen N, et al. Splicing modulators act at the branch point adenosine binding pocket defined by the PHF5A-SF3b complex. Nature Communications. 8: 15522. PMID 28541300 DOI: 10.1038/Ncomms15522 |
0.329 |
|
2017 |
Smith PG, Puyang X, Furman C, Zheng GZ, Banka D, Thomas M, Subramanian V, Irwin S, Larsen N, Caleb B, Karr C, Wu J, O’Shea M, Yang J, Davis A, et al. Abstract DDT01-04: Discovery and development of H3B-6545: A novel, oral, selective estrogen receptor covalent antagonist (SERCA) for the treatment of breast cancer Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Ddt01-04 |
0.316 |
|
2016 |
Cowen SD, Russell D, Dakin LA, Chen H, Larsen NA, Godin R, Throner S, Zheng X, Molina A, Wu J, Cheung T, Howard T, Garcia-Arenas R, Keen N, Pendleton CS, et al. Design, Synthesis, and Biological Activity of Substrate Competitive SMYD2 Inhibitors. Journal of Medicinal Chemistry. 59: 11079-11097. PMID 28002961 DOI: 10.1021/Acs.Jmedchem.6B01303 |
0.351 |
|
2016 |
Dowling JE, Alimzhanov M, Bao L, Chuaqui C, Denz CR, Jenkins E, Larsen NA, Lyne PD, Pontz T, Ye Q, Holdgate GA, Snow L, O'Connell N, Ferguson AD. Potent and Selective CK2 Kinase Inhibitors with Effects on Wnt Pathway Signaling in Vivo. Acs Medicinal Chemistry Letters. 7: 300-5. PMID 26985319 DOI: 10.1021/Acsmedchemlett.5B00452 |
0.309 |
|
2016 |
Teng T, Puyang X, Peng S, Feala J, Chan B, Tsai J, Caleb B, Karr C, Park E, Corson L, Mizui Y, Smith P, Larsen N, Yu L, Warmuth M, et al. Abstract 3013: Identification of PHF5A as a common cellular target of splicing-modulating chemical probes Cancer Research. 76: 3013-3013. DOI: 10.1158/1538-7445.Am2016-3013 |
0.352 |
|
2015 |
Johannes JW, Almeida L, Daly K, Ferguson AD, Grosskurth SE, Guan H, Howard T, Ioannidis S, Kazmirski S, Lamb ML, Larsen NA, Lyne PD, Mikule K, Ogoe C, Peng B, et al. Discovery of AZ0108, an orally bioavailable phthalazinone PARP inhibitor that blocks centrosome clustering. Bioorganic & Medicinal Chemistry Letters. PMID 26546219 DOI: 10.1016/J.Bmcl.2015.10.079 |
0.326 |
|
2015 |
Kowalczyk P, Węgrzyn P, Prokopowicz M, Knop M, Mazur K, Dziedzic K, Gluza K, Radzimierski A, Commandeur C, Zawadzka M, Bloudoff K, Vaillancourt F, Larsen N, Wang J, Reynolds D, et al. Abstract C26: Development of selective MELK kinase inhibitors for breast cancer treatment Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-C26 |
0.307 |
|
2013 |
Dowling JE, Alimzhanov M, Bao L, Block MH, Chuaqui C, Cooke EL, Denz CR, Hird A, Huang S, Larsen NA, Peng B, Pontz TW, Rivard-Costa C, Saeh JC, Thakur K, et al. Structure and Property Based Design of Pyrazolo[1,5-a]pyrimidine Inhibitors of CK2 Kinase with Activity in Vivo. Acs Medicinal Chemistry Letters. 4: 800-5. PMID 24900749 DOI: 10.1021/Ml400197U |
0.356 |
|
2013 |
Wu J, Powell F, Larsen NA, Lai Z, Byth KF, Read J, Gu RF, Roth M, Toader D, Saeh JC, Chen H. Mechanism and in vitro pharmacology of TAK1 inhibition by (5Z)-7-Oxozeaenol. Acs Chemical Biology. 8: 643-50. PMID 23272696 DOI: 10.1021/Cb3005897 |
0.342 |
|
2012 |
Dowling JE, Chuaqui C, Pontz TW, Lyne PD, Larsen NA, Block MH, Chen H, Su N, Wu A, Russell D, Pollard H, Lee JW, Peng B, Thakur K, Ye Q, et al. Potent and Selective Inhibitors of CK2 Kinase Identified through Structure-Guided Hybridization. Acs Medicinal Chemistry Letters. 3: 278-83. PMID 24900464 DOI: 10.1021/Ml200257N |
0.333 |
|
2012 |
Martínez-Botella G, Breen JN, Duffy JE, Dumas J, Geng B, Gowers IK, Green OM, Guler S, Hentemann MF, Hernandez-Juan FA, Joseph-McCarthy D, Kawatkar S, Larsen NA, Lazari O, Loch JT, et al. Discovery of selective and potent inhibitors of gram-positive bacterial thymidylate kinase (TMK). Journal of Medicinal Chemistry. 55: 10010-21. PMID 23043329 DOI: 10.1021/Jm3011806 |
0.322 |
|
2012 |
Larsen NA, Nash TJ, Morningstar M, Shapiro AB, Joubran C, Blackett CJ, Patten AD, Boriack-Sjodin PA, Doig P. An aminoquinazoline inhibitor of the essential bacterial cell wall synthetic enzyme GlmU has a unique non-protein-kinase-like binding mode. The Biochemical Journal. 446: 405-13. PMID 22721802 DOI: 10.1042/Bj20120596 |
0.403 |
|
2012 |
Wang T, Block MA, Cowen S, Davies AM, Devereaux E, Gingipalli L, Johannes J, Larsen NA, Su Q, Tucker JA, Whitston D, Wu J, Zhang HJ, Zinda M, Chuaqui C. Discovery of azabenzimidazole derivatives as potent, selective inhibitors of TBK1/IKKε kinases. Bioorganic & Medicinal Chemistry Letters. 22: 2063-9. PMID 22305584 DOI: 10.1016/J.Bmcl.2012.01.018 |
0.33 |
|
2012 |
Hennessy EJ, Saeh JC, Sha L, MacIntyre T, Wang H, Larsen NA, Aquila BM, Ferguson AD, Laing NM, Omer CA. Discovery of aminopiperidine-based Smac mimetics as IAP antagonists. Bioorganic & Medicinal Chemistry Letters. 22: 1690-4. PMID 22264476 DOI: 10.1016/J.Bmcl.2011.12.109 |
0.347 |
|
2012 |
MacIntyre T, Powell F, Lewis P, Adam A, Lawson D, Wu J, Larsen N, Repik G, Parmentier J, Secrist P, Ioaniddis S, Byth K. Abstract 2011: A novel bcl-2/xL inhibitor induces tumor cell apoptosis and potentiates the activity of standard chemotherapeutics Cancer Research. 72: 2011-2011. DOI: 10.1158/1538-7445.Am2012-2011 |
0.304 |
|
2011 |
Ferguson AD, Larsen NA, Howard T, Pollard H, Green I, Grande C, Cheung T, Garcia-Arenas R, Cowen S, Wu J, Godin R, Chen H, Keen N. Structural basis of substrate methylation and inhibition of SMYD2. Structure (London, England : 1993). 19: 1262-73. PMID 21782458 DOI: 10.1016/J.Str.2011.06.011 |
0.345 |
|
2007 |
Larsen NA, Al-Bassam J, Wei RR, Harrison SC. Structural analysis of Bub3 interactions in the mitotic spindle checkpoint. Proceedings of the National Academy of Sciences of the United States of America. 104: 1201-6. PMID 17227844 DOI: 10.1073/Pnas.0610358104 |
0.318 |
|
2006 |
Cooper ZD, Narasimhan D, Sunahara RK, Mierzejewski P, Jutkiewicz EM, Larsen NA, Wilson IA, Landry DW, Woods JH. Rapid and robust protection against cocaine-induced lethality in rats by the bacterial cocaine esterase. Molecular Pharmacology. 70: 1885-91. PMID 16968810 DOI: 10.1124/Mol.106.025999 |
0.431 |
|
2004 |
Larsen NA, de Prada P, Deng SX, Mittal A, Braskett M, Zhu X, Wilson IA, Landry DW. Crystallographic and biochemical analysis of cocaine-degrading antibody 15A10. Biochemistry. 43: 8067-76. PMID 15209502 DOI: 10.1021/Bi049495L |
0.491 |
|
2003 |
Redwan el-RM, Larsen NA, Zhou B, Wirsching P, Janda KD, Wilson IA. Expression and characterization of a humanized cocaine-binding antibody. Biotechnology and Bioengineering. 82: 612-8. PMID 12652485 DOI: 10.1002/Bit.10598 |
0.475 |
|
2003 |
Zhu X, Larsen NA, Basran A, Bruce NC, Wilson IA. Observation of an arsenic adduct in an acetyl esterase crystal structure. The Journal of Biological Chemistry. 278: 2008-14. PMID 12421810 DOI: 10.1074/Jbc.M210103200 |
0.485 |
|
2002 |
Larsen NA, Heine A, de Prada P, Redwan el-R, Yeates TO, Landry DW, Wilson IA. Structure determination of a cocaine hydrolytic antibody from a pseudomerohedrally twinned crystal. Acta Crystallographica. Section D, Biological Crystallography. 58: 2055-9. PMID 12454464 DOI: 10.1107/S0907444902017420 |
0.446 |
|
2002 |
Turner JM, Larsen NA, Basran A, Barbas CF, Bruce NC, Wilson IA, Lerner RA. Biochemical characterization and structural analysis of a highly proficient cocaine esterase. Biochemistry. 41: 12297-307. PMID 12369817 DOI: 10.1021/Bi026131P |
0.475 |
|
2002 |
Larsen NA, Turner JM, Stevens J, Rosser SJ, Basran A, Lerner RA, Bruce NC, Wilson IA. Crystal structure of a bacterial cocaine esterase. Nature Structural Biology. 9: 17-21. PMID 11742345 DOI: 10.1038/Nsb742 |
0.485 |
|
2001 |
Larsen NA, Heine A, Crane L, Cravatt BF, Lerner RA, Wilson IA. Structural basis for a disfavored elimination reaction in catalytic antibody 1D4. Journal of Molecular Biology. 314: 93-102. PMID 11724535 DOI: 10.1006/Jmbi.2001.5112 |
0.445 |
|
2001 |
Wentworth P, Jones LH, Wentworth AD, Zhu X, Larsen NA, Wilson IA, Xu X, Goddard WA, Janda KD, Eschenmoser A, Lerner RA. Antibody catalysis of the oxidation of water. Science (New York, N.Y.). 293: 1806-11. PMID 11546867 DOI: 10.1126/Science.1062722 |
0.381 |
|
2001 |
Larsen NA, Zhou B, Heine A, Wirsching P, Janda KD, Wilson IA. Crystal structure of a cocaine-binding antibody. Journal of Molecular Biology. 311: 9-15. PMID 11469854 DOI: 10.1006/Jmbi.2001.4839 |
0.461 |
|
2000 |
Karlstrom A, Zhong G, Rader C, Larsen NA, Heine A, Fuller R, List B, Tanaka F, Wilson IA, Barbas CF, Lerner RA. Using antibody catalysis to study the outcome of multiple evolutionary trials of a chemical task. Proceedings of the National Academy of Sciences of the United States of America. 97: 3878-83. PMID 10760259 DOI: 10.1073/Pnas.97.8.3878 |
0.426 |
|
Show low-probability matches. |